Brokerages expect that Pfizer Inc. (NYSE:PFE) will post $13.28 billion in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Pfizer’s earnings. The highest sales estimate is $13.31 billion and the lowest is $13.23 billion. Pfizer posted sales of $12.90 billion during the same quarter last year, which suggests a positive year over year growth rate of 2.9%. The company is expected to issue its next earnings results before the market opens on Tuesday, July 31st.
According to Zacks, analysts expect that Pfizer will report full-year sales of $54.42 billion for the current fiscal year, with estimates ranging from $54.00 billion to $54.96 billion. For the next year, analysts anticipate that the firm will report sales of $54.94 billion per share, with estimates ranging from $54.35 billion to $55.90 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Pfizer.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.03. The firm had revenue of $12.91 billion during the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.69 EPS.
Several research firms have recently commented on PFE. Cantor Fitzgerald began coverage on Pfizer in a research report on Thursday, June 7th. They issued an “overweight” rating and a $45.00 price target for the company. Morgan Stanley reissued a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research report on Monday, June 11th. Credit Suisse Group set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Monday, June 11th. Jefferies Financial Group set a $38.00 price target on Pfizer and gave the stock a “hold” rating in a research report on Friday, April 13th. Finally, Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, April 12th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $40.27.
Shares of Pfizer traded up $0.03, hitting $36.31, during trading hours on Friday, according to Marketbeat. The company had a trading volume of 789,850 shares, compared to its average volume of 20,688,782. The firm has a market cap of $215.97 billion, a price-to-earnings ratio of 13.67, a PEG ratio of 1.80 and a beta of 0.93. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45. Pfizer has a one year low of $32.32 and a one year high of $39.43.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, August 3rd will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, August 2nd. This represents a $1.36 annualized dividend and a yield of 3.75%. Pfizer’s dividend payout ratio (DPR) is 51.32%.
In other Pfizer news, Director W Don Cornwell sold 5,223 shares of the business’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $36.40, for a total transaction of $190,117.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 132,312 shares of the business’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 156,535 shares of company stock worth $5,647,222. 0.06% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of PFE. Ballew Advisors Inc acquired a new position in shares of Pfizer in the 1st quarter valued at about $102,000. Earnest Partners LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $105,000. First Dallas Securities Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at about $118,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in shares of Pfizer in the 4th quarter valued at about $118,000. Finally, Delpha Capital Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $126,000. Institutional investors and hedge funds own 69.45% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.